



Early Detection Saves Lives

We are a health innovation company transforming breast health awareness through accessible, technology-driven solutions.

The Urgent Need for Early Detection

Understanding the Numbers

Breast cancer is the leading cause of death among women globally, with 1 in 8 women diagnosed. Despite this alarming rate, access to early detection remains severely limited, which compounds the urgency for innovative solutions that can make screening more accessible and effective for all.

Every 46 seconds... 

Worldwide: A woman dies every from breast cancer.

In the EU, it is every 5.5 minutes.

In the USA, it is every 12 minutes.

Early detection survival rates are above 90% yet drop to 40% or less when found later.

AND THIS IS SIMPLY, NOT ACCEPTABLE!



The Luminous Pro Series: A Life-Saving Innovation



Patented Technology

Our Luminous Pro Series is a medical device that uses patented red LED technology within 620 -800 nanometers to illuminate breast tissue to reveal vascular patterns and potential anomalies in minutes.

CE Marked Class I for Safety and Reliability

Our Luminous Pro Series is CE Marked Class I medical device, ensuring that it meets the highest standards of safety and effectiveness for early breast cancer detection. This includes meeting MDR standards in Europe.

Non-Invasive, Non-Toxic, Radiation Free and User-Friendly Design

Designed with users in mind, the Luminous Pro offers a non-invasive approach that prioritizes comfort and simplicity in home diagnostics.

Accessible Healthcare for Everyone

Technology is the great equalizer! With our focus on affordability, the Luminous Pro Series medical device alongside the Luminous app, we aim to make early detection accessible to all women, regardless of their economic background.



Science and Validation of Luminous Pro



Proven effectiveness in early detection

The **Luminous Pro Series** medical device is backed by a peer reviewed, double blind **IRB-approved study** demonstrating 89.6% sensitivity and 96.4% specificity. Backed by a renowned Scientific & Clinical Advisory Board of Oncologists, Radiologists, and Researchers.


These results underscore the device's ability to accurately identify early signs of breast cancer, ensuring timely intervention and **improving survival rates** for women.

Currently in the process of seeking approval from the FDA for launch in Q2 2026.



Addressable Market Insights for Luminous Pro Series

Total Addressable Market (TAM) Overview



Diverse Revenue Streams for Luminous Pro

Understanding how we monetize our product

Device Sales: Direct Consumer Purchases (D2C)

The Luminous Pro Series will generate revenue through **direct sales** to consumers via online platforms, retail partnerships, affiliates and endorsements. This approach ensures accessibility, allowing customers to purchase our home diagnostic tool easily and efficiently.

App Subscriptions: Enhanced User Engagement

The Luminous App is FREE, although there will be a paid subscription tier that offers premium features & content **enhancing the user experience and engagement**. This model not only provides ongoing support but also generates recurring revenue, contributing to long-term profitability and customer retention.

Data Licensing: Collaborations with Healthcare Entities

Through the AI capabilities of the second generation Luminous Pro Series device, UR Luminous will work with healthcare providers and research organizations by licensing **anonymized data** collected through our devices. This collaboration not only fosters innovation in diagnostics but also creates a new revenue stream, supporting further research and development initiatives.

Collaborations with Private Corporations, Wellness Programs & Governments

Establish strategic partnerships with private corporations, wellness networks, and government health agencies to integrate the Luminous Pro Series into large-scale wellness, early-detection, and public health initiatives. These collaborations create multi-channel revenue opportunities through **bulk device purchases, program sponsorships, and institutional licensing** agreements that advance women's health globally.



Traction and Impact: Our Growth Story



Expanding Across 28 EU Markets

We have successfully launched in 28 different EU markets + UK, significantly increasing our foot traffic and engaging with local healthcare systems. Brazil, Peru and Mexico are in the works.

Empowering Over 10,000 Women Screened


Our innovative device has already screened over **10,000 women**, providing them with early detection and peace of mind regarding their health.

Launched the Non-profit Luminous Advocacy Project 501(3) C

Early detection of possible breast abnormalities by driving forward research, education and medical support in underserving countries and communities.



SilkPro USA Business Timeline



About Luminous Advocacy Project

Luminous Advocacy Project 501(3) C

MISSION: To educate women and men on the need to be proactive with their breast health by disseminating awareness and equipping them with a tool that can make visually referencing their breast health easier to do.

We are focused on investing in the future of breast health around the world and living an awareness lifestyle.



Competitive Advantage of Luminous Pro Series

Key Differentiators from Existing Solutions

Technology	Light Type	Core Principle	Pricing	Key Strengths	Limitations
Optical/Diffuse Optical Mammography	Red/NIR (600–1100 nm)	Spectral tissue composition analysis	\$55K - \$75K	Non-invasive; tissue characterization	Lower spatial resolution
CTLM	NIR (~808 nm)	Laser tomography of hemoglobin distribution	\$246 - \$535/visit w/insurance	No radiation; high sensitivity in dense tissue	Requires interpretation; FDA pending
NIR Tomographic Therapy Response	Red/NIR	Measures blood flow dynamics for therapy	\$50K - \$200K	Early prediction of chemo response	Mostly research/pilot phase
Luminous Pro Series (LED Device)	LED Red (640–800 nm)	Visible screening of abnormalities	\$369	Simple; CE Marked Class I - Pending FDA, hand held, Radiation free	Limited clinical validation.
DATG	Thermal (IR)	Temporal vascular heat mapping	\$15K - \$120K, Patient OOP \$150/scan	Low-cost; non-invasive	Used adjunctively, not standalone, not portable
DCS	NIR	Measures microvascular blood flow	\$15K - \$100K	Real-time perfusion data	Emerging research tool
MSOT	Multispectral light + ultrasound	Functional/structural imaging	\$50K - \$500K	High-resolution vascular imaging	Complex equipment; research stage



Strategic Rollout Plan

Building partnerships for maximum impact

MODEL	PARTNER TYPE	STRUCTURE	VALUE TO UR LUMINOUS
Corporate Wellness	Employers / Insurers	Employee Health Program integration	Volume Sales & Brand Reach
Reimbursement Pilot	Insurers / Government	Preventive care coverage for device use	Scalable recurring revenue
Hospital Endorsement	Hospitals / Clinics	Device endorsement & resale	Clinical validation & data
Public Health Pilot	Governments / NGO's	Subsidized distribution and education campaigns	Public trust + visibility
Global Health Subsidy	NGO's / Donors	Device donation & co-funding	Access to emerging markets

Our objective is to integrate early breast awareness into national and private health ecosystems worldwide. The **go-to-market strategy** includes multi-sector financial and strategic partnerships that position UR Luminous and the Luminous Pro Series device as a cornerstone of early breast health awareness and preventive diagnostics globally. We will have a regional and opportunistic worldwide focus.

- Regional Focus: United States · Europe - Government pilots, private corporations, insurer alignment/reimbursement, public health adoption and hospital network integration.
- Developing Nations (3rd World Countries) - NGO collaborations and global health deployment for low-resource areas.



Financial Summary and Projections for Investors

Key Financial Metrics Over Three Years

YEAR	2026	2027	2028
Luminous Pro Series - Units	75,000	125,000	200,000
(+/- WP \$269) Revenues	\$ 20,175,000	\$ 33,625,000	\$ 53,800,000
Luminous Gen II - Unit	30,000	120,000	180,000
(+/- WP \$469) Revenues	\$ 14,070,000	\$ 56,280,000	\$ 84,420,000
Total Gross Revenue	\$ 34,245,000	\$ 89,905,000	\$ 138,220,000
Net Profit (60% GR)	\$ 20,547,000	\$ 53,943,000	\$ 82,932,000
Net 15X = Value	\$ 308,205,000	\$ 809,145,000	\$ 1,243,980,000

**WP = Wholesale Price

NOTE: These projections do not include the launch of new products that are currently in R&D.

Disclaimer: The financial projections contained herein represent estimates based on information available at the time of preparation. These projections are forward-looking statements that involve risks and uncertainties. Actual results may vary significantly from the projections due to various factors, including but not limited to market conditions, changes in economic circumstances, regulatory changes, and unforeseen events.



Meet Our Leadership Team and Advisors



Marilyn Dans
Founder / CEO

Our CEO, Marilyn Dans, brings over 20 years of experience in healthcare innovation and leadership to UR Luminous, driving our mission forward.



Dr. Lin Yang PHDs, MBA
CTO

Dr. Lin Yang, our CTO, is an expert in diagnostic technology, ensuring our products meet the highest standards of safety and efficacy.



Loreyne Alica
Chief Operating Officer

COO - Loreyne Alica leads global operations, strategic growth and marketing functions. She brings 28+ years of experience transforming ideas into revenues across industries —CPG, SaaS, fintech and media.



Raymond Garcia
Chief Financial Officer

Raymond Garcia oversees financial strategy and sustainability. With extensive experience in healthcare and technology, he drives operational excellence and global expansion, ensuring UR Luminous remains fiscally strong and strategically positioned for continued growth.



Glenn Normoyle
Vice President, Global Strategy

VP of Global Strategy - Glenn Normoyle President of - NeoGraft® Solutions; Sold to Venus Concept; Extensive background in medical device / healthcare CPG sales and marketing from launch to exist in both DTC and BTB.



Meet Our Leadership Team and Advisors



Dr. Amy Yee, PhD
Scientific Advisor, Oncology and Biotech Innovation

Dr. Amy Yee, founder of Cha Therapeutics and professor at Tufts University, is a leader in cancer research and biotechnology. She drives translational innovation to develop breakthrough therapies that improve patient outcomes.



Dr. Ira Lawrence, MD
Medical and Innovation Advisor

Dr. Ira Lawrence leverages decades of experience in medical product development. As CMO at Alphaeon and Medisis, he advances global innovation, guiding regulatory and strategic efforts in medical and aesthetic healthcare.



Dr. Howard Petty, PhD
Scientific Advisor, Precision Oncology

Dr. Howard Petty, co-founder of Predictoma Inc., is a Harvard and Stanford-affiliated researcher. He develops AI-powered cancer diagnostics that advance precision medicine and improve outcomes in oncology care.



Dr. Dipanjan Pan, PhD, FRSC, FAIMBE, FRSB, FAHA, FACC, FGAN

Dorothy Foehr Huck & J. Lloyd Huck Chair Professor in Nanomedicine at the Pennsylvania State University. Associate Editor Nanomedicine Nanobiotechnology at Wiley; Chief Technology Officer and Co-Founder at Insight Tech.



Dr. John P. Diaz, MD
Clinical Advisor, Gynecologic Oncology

Dr. John P. Diaz, Chief of Gynecologic Oncology at Miami Cancer Institute, is a leader in minimally invasive surgery. He advances precision care and improves outcomes for women facing gynecologic cancers.

Wiley



Investment Opportunities for UR Luminous

Join us in transforming women's health

Fundraising Goal and Valuation

We are aiming to raise **\$4.5 Million** at a valuation of **\$40.0 M**. This funding will enable us to accelerate our market entry and enhance product development, ensuring we meet the urgent needs of women's health diagnostics.

Allocation of Funds

The raised capital will be strategically allocated across key areas: **product development**, evolve 2nd gen Luminous Pro Series **manufacturing**, expanding production; **marketing**, moving from to enhance education and brand visibility to sales conversion; and **regulatory** efforts, finalizing the legal processes and securing FDA approval.

Expected 18-Month Runway

With the current fundraising, we anticipate an **18-month runway** that will provide the necessary resources to establish our market presence, develop partnerships, and achieve vital sales milestones in our expansion plans.



Check. Detect. Protect.

Join the Movement for Women's Health

By investing in **UR Luminous**, you're not just supporting a product; you're joining a mission to revolutionize early detection. Together, we can reshape the future of women's health and save countless lives through accessible technology.

Luminous Pro Series – the first line of defense!



Supporting Materials and Documentation

Essential documents to validate our claims

Certifications and Clinical Evidence

Our commitment to quality and safety is evident through our **certifications and clinical studies**. Included are IRB-approved research documents, recognition from health authorities, and press mentions that highlight our impact and credibility in the health tech sector. These materials reinforce our mission and support investor confidence.

RECENT PUBLISHED ARTICLE FROM HEALTH SCIENCES - "Revolutionizing Early Detection: A Cross-Sectional Comparative Study of Pink Luminous Screening Versus Breast Self-Examination Among Nursing Students"





CLINICAL TRAIL



DELOITTE VALUATION



FRONTIER PEER REVIEW



VIDEOS SHOWING IRREGULAR
VENOUS FLOW... VASCULARITY...
ANDIOGENESIS...



MEDICAL
MISSION DATA



STUDY OF LUMINOUS
DEVICE SCREENING 2024



Luminous

Pro-Series



Luminous is safe, non-invasive, and radiation-free, making it ideal for regular use with complete peace of mind.



www.urluminous.com

